Finance
Alexza, Symphony Capital enter into $50 million product development collaboration
Published in Drug Week, January 5th, 2007
AZ-002 is being developed for the acute treatment of panic attacks associated with panic disorder and AZ-004 is being developed to treat acute agitation in patients with schizophrenia. Both product candidates are currently in phase IIa clinical trials.
Under the terms of the agreement, Alexza and Symphony Capital, a private equity firm, have established Symphony Allegro, Inc., which will provide funding...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2007-01-05)
More Articles from Drug Week
- Cervical Cancer
Hycamtin indication expanded to include cervical cancer treatment in combination with cisplatin - Drug Development
Memory Pharmaceuticals presents data on CNS-related drug candidates at neuroscience meeting - Alzheimer Disease Therapy
Research on alzheimer disease therapy published by scientists at Schering Plough Research Institute, Department of Neurobiology - Aneurysm Therapy
Research findings from Hacettepe University, Department of Radiology update understanding of aneurysm therapy - Angiogenesis
Studies from Swiss Federal Institute of Technology in the area of angiogenesis described - Angioplasty
Research from Freeman Hospital, Radiology Department in angioplasty provides new insights - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
